Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells.
B cells
CD4 T cells
CD8 T cells
COVID-19
SARS-CoV-2
binding antibody
coronaviruses
immune correlates
immune memory
neutralizing antibody
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
20 07 2021
20 07 2021
Historique:
received:
17
04
2021
revised:
27
05
2021
accepted:
24
06
2021
pubmed:
13
7
2021
medline:
13
7
2021
entrez:
12
7
2021
Statut:
ppublish
Résumé
Ending the COVID-19 pandemic will require long-lived immunity to SARS-CoV-2. Here, we evaluate 254 COVID-19 patients longitudinally up to 8 months and find durable broad-based immune responses. SARS-CoV-2 spike binding and neutralizing antibodies exhibit a bi-phasic decay with an extended half-life of >200 days suggesting the generation of longer-lived plasma cells. SARS-CoV-2 infection also boosts antibody titers to SARS-CoV-1 and common betacoronaviruses. In addition, spike-specific IgG+ memory B cells persist, which bodes well for a rapid antibody response upon virus re-exposure or vaccination. Virus-specific CD4+ and CD8+ T cells are polyfunctional and maintained with an estimated half-life of 200 days. Interestingly, CD4+ T cell responses equally target several SARS-CoV-2 proteins, whereas the CD8+ T cell responses preferentially target the nucleoprotein, highlighting the potential importance of including the nucleoprotein in future vaccines. Taken together, these results suggest that broad and effective immunity may persist long-term in recovered COVID-19 patients.
Identifiants
pubmed: 34250512
doi: 10.1016/j.xcrm.2021.100354
pii: S2666-3791(21)00203-2
pmc: PMC8253687
doi:
Substances chimiques
Antibodies, Viral
0
Spike Glycoprotein, Coronavirus
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
100354Subventions
Organisme : NIAID NIH HHS
ID : U19 AI090023
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI150747
Pays : United States
Organisme : NIH HHS
ID : P51 OD011132
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI057266
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068618
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA260563
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068635
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI074492
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069481
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Curr Genet Med Rep. 2021;9(1):1-12
pubmed: 33457109
PLoS Negl Trop Dis. 2018 Oct 24;12(10):e0006862
pubmed: 30356267
Cell. 2021 Jan 7;184(1):169-183.e17
pubmed: 33296701
Cell Host Microbe. 2021 Apr 14;29(4):516-521.e3
pubmed: 33798491
Epidemiol Infect. 1990 Oct;105(2):435-46
pubmed: 2170159
Nature. 2020 Aug;584(7819):115-119
pubmed: 32454513
J Immunol Methods. 2007 May 31;323(1):39-54
pubmed: 17451739
Biostatistics. 2004 Apr;5(2):155-76
pubmed: 15054023
Nat Commun. 2021 Feb 19;12(1):1162
pubmed: 33608522
Science. 2020 Oct 9;370(6513):237-241
pubmed: 32792465
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Nature. 1997 Jul 10;388(6638):133-4
pubmed: 9217150
Curr Protoc Immunol. 2020 Dec;131(1):e116
pubmed: 33215858
Cytometry A. 2019 Jul;95(7):722-725
pubmed: 30919583
Nat Med. 2003 Sep;9(9):1131-7
pubmed: 12925846
Cell Rep Med. 2020 Jun 23;1(3):100040
pubmed: 32835303
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Biostatistics. 2014 Jan;15(1):87-101
pubmed: 23887981
JAMA. 2020 Oct 6;324(13):1279-1281
pubmed: 32915201
Science. 2020 Sep 18;369(6510):1501-1505
pubmed: 32703906
Nat Med. 2020 Nov;26(11):1691-1693
pubmed: 32929268
Cell Host Microbe. 2020 May 13;27(5):841-848.e3
pubmed: 32289263
N Engl J Med. 2021 Jun 10;384(23):2259-2261
pubmed: 33822494
Clin Infect Dis. 2018 Mar 19;66(7):1099-1108
pubmed: 29140432
Immunity. 1998 Mar;8(3):363-72
pubmed: 9529153
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
N Engl J Med. 2020 Dec 17;383(25):2427-2438
pubmed: 32991794
Nature. 2020 Aug;584(7821):443-449
pubmed: 32668443
Nature. 2017 Dec 21;552(7685):362-367
pubmed: 29236685
N Engl J Med. 2007 Nov 8;357(19):1903-15
pubmed: 17989383
Immunity. 2020 Jul 14;53(1):98-105.e5
pubmed: 32561270
Front Psychol. 2017 Apr 07;8:456
pubmed: 28439244
JAMA. 2021 Apr 6;325(13):1261-1262
pubmed: 33571363
Science. 2021 Feb 12;371(6530):741-745
pubmed: 33436525
Science. 2021 Mar 25;:
pubmed: 33766944
Nat Immunol. 2016 Oct;17(10):1226-34
pubmed: 27525369
Nature. 2021 Jul;595(7867):421-425
pubmed: 34030176
N Engl J Med. 2021 May 13;384(19):1824-1835
pubmed: 33440088
PLoS Comput Biol. 2021 Oct 14;17(10):e1009468
pubmed: 34648489